Trial Profile
A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CCTG IND 232
- 25 Aug 2023 Planned End Date changed from 30 Dec 2022 to 30 Jun 2024.
- 14 Mar 2022 Planned End Date changed from 30 Jun 2022 to 30 Dec 2022.
- 10 Jan 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.